Conclusions

Faropenem, a stable and orally bioavailable β-lactam, has broad-spectrum in vitro antimicrobial activity against many Gram-positive and Gram-negative aerobes and anaerobes and is resistant to hydrolysis by nearly all β-lactamases. A 7-day regimen of faropenem is effective in the treatment of uncomplicated cystitis. Faropenem is a potential solution to combat the emergence of resistance among respiratory tract pathogens. It is an alternative to fluoroquinolones or macrolides/ketolides when there is a concern with resistant pathogens.